PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility

Standard road crossing intervals are often too short for older adults with limited mobility, research reveals

2025-12-08
(Press-News.org) Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated. 

The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.  

Led by Dr Max Western from the University of Bath Centre for Motivation and Behaviour Change, the study found that just 1.5% of older adults with mobility limitations walk fast enough at their comfortable speed to cross the road within the time normally allowed by pedestrian signals. 

The research analysed walking speeds of 1,110 adults aged 65 and over from two major UK trials. Their average walking speed was 0.77 metres per second, well below the 1.2 m/s assumed by most pedestrian crossing designs. This means the average participant would take 6.5 seconds to cross a 5-metre road – over two seconds more than the green crossing signal typically allows. 

Dr Max Western said: “Current crossing times might be unrealistic for many older people who face challenges with their mobility. This isn’t just a safety issue – it’s potentially a barrier to independence, physical activity, and social connection, all of which often decline in later life.” 

The study also found that older age, lower strength and balance were associated with slower walking speeds. Over half of participants would need to increase their comfortable walking speed by 50% or more to cross an average road safely. 

Professor Afroditi Stathi from the University of Birmingham, who leads the two UK research trials underpinning the findings, commented: “Older adults often face challenges staying active and connected, especially when mobility is reduced. Designing outdoor spaces that work for everyone – such as allowing enough time to cross the road – can boost confidence, support independence, and help them remain engaged in their communities - all key to a better quality of life.” 

A Call for Change  The researchers argue that even small changes, such as extending green signal times by a few seconds, could make a big difference. They propose adjusting crossing times to reflect a more realistic walking speed of 0.7 m/s, which would allow more people to cross safely and confidently. 

While innovations like smart crossings and countdown timers are emerging, the team warns that without targeted public awareness and inclusive design, these technologies may not benefit those most in need. 

The research team is calling for: 

The adoption of urban design standards that account for slower walking speeds by extending crossing times and improving pedestrian safety features. This ensures older adults can move confidently and remain active in their communities. 

The integration of mobility support into public health strategies by creating age-friendly outdoor spaces such as safe walkways, benches, and extended crossing times to encourage regular physical activity among older adults 

The paper, Why didn’t the senior citizen cross the road? Gait speed in community-dwelling older adults with mobility limitations relative to pedestrian crossing times, is published in Age and Ageing today, Monday 8 December (DOI: 10.1093/ageing/afaf345). 

The research paper presents a secondary analysis of data collected as part of two NIHR Public Health Research Programme grants (reference: 13/164/51 and 130156).  

 

ENDS 

 

For more information, contact Will McManus in the University of Bath press office: wem25@bath.ac.uk / press@bath.ac.uk / +44(0)1225 385 798 

A copy of the research paper can be supplied on request. 

University of Bath 

The University of Bath is one of the UK's leading universities, recognised for high-impact research, excellence in education, an outstanding student experience and strong graduate prospects. 

We are ranked among the top 10% of universities globally, placing 132nd in the QS World University Rankings 2026. 

We are ranked in the top 10 in all of the UK’s major university guides. 

The University achieved a triple Gold award in the last Teaching Excellence Framework 2023, the highest awards possible, for both the overall assessment and for student outcomes and student experience. The Teaching Excellence Framework (TEF) is a national scheme run by the Office for Students (OfS). 

We are The Times and The Sunday Times Sport University of the Year 2026. 

Research at Bath is shaping a better future through innovation in sustainability, health, and digital technologies. Find out all about our Research with Impact: http://bit.ly/3ISz1Wu  

 

END


ELSE PRESS RELEASES FROM THIS DATE:

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

2025-12-07
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 7, 2025, AT 6:00 P.M. EST) – Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.   Early findings from the LIFE-L study will be presented on behalf of the multidisciplinary team by Melissa Lopez, Ph.D., RDN, at the American Society of Hematology (ASH) annual meeting in Orlando. Lopez is a postdoctoral ...

A sound defense: Noisy pupae puff away potential predators

2025-12-07
Insect pupae hiss like snakes for defense. A Kobe University team now reveals the mechanisms, opening the door to further studies involving predator reactions to defensive sounds. Just as you would shout or make noise to drive off a perceived threat, some insects have been known to produce defensive sounds. Some moths, for example, have been observed producing sounds to ward off predators at multiple developmental stages; pupal sound production has so far been attributed mainly to physical friction between body parts. “We became interested in this topic when ...

Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy

2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax combination (known as aza-ven) is the standard of care for older adults who are not fit enough for intensive chemotherapy. The trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients. “Our study met ...

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone. The study is the first reported randomized controlled trial to test a bispecific antibody combination in follicular lymphoma and suggests the combination could offer an effective alternative to chemotherapy that can be safely administered on an outpatient basis. Based on the study results, the U.S. Food and Drug Administration (FDA) approved epcoritamab with ...

New findings support a chemo-free approach for treating Ph+ ALL

2025-12-07
(ORLANDO, Dec. 7, 2025) A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL. Researchers say the findings offer reassurance that chemotherapy can be omitted without detrimental effects and suggest that a chemo-free targeted agent and immunotherapy combination could become the new standard of care for this patient group. “The chemo-free approach ...

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

2025-12-07
(ORLANDO, Dec. 7, 2025) Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Non-covalent BTK inhibitors were initially developed to overcome resistance to covalent ...

University of Cincinnati experts present research at annual hematology event

2025-12-06
University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6 to 9 in Orlando. Phase 1 data testing new CLL treatment encouraging  A class of drugs called BTK inhibitors have become a standard treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). However, the prevalence of new resistance mutations has created  a need for new treatments in patients with relapsed CLL who progressed through approved standard of care options, said the Cancer Center’s Zulfa Omer, MD. “This is an area of unmet need, with current options providing ...

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

2025-12-06
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 2:00 P.M. EST) – Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. The findings will be presented Dec. 6, 2025, at the American Society of Hematology (ASH) annual meeting in Orlando. None of the 18 patients who completed up to six cycles of treatment with the antibody linvoseltamab had detectable disease on highly sensitive tests. This preliminary ...

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

2025-12-06
Article Summary: Researchers found that DNA’s shape matters. When its loops break, cancer can start. Based on a new concept of architectural tumor suppression, researchers used proteins that organize DNA to also help prevent lymphoma. Artificial intelligence helped reveal the changes that could guide future treatments. MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 9:50 A.M. EST) – Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, ...

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

2025-12-06
Article Summary ACCESS study reveals patients can safely receive stem cell transplants from unrelated donors with multiple genetic mismatches. A protective regimen acts as a “bridge,” preventing complications and boosting survival rates. Findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry. Study will be presented at ASH Dec. 8 and will also be highlighted in a special ASH press briefing Dec. 6 at 8:30AM EST. MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 8:30AM) – For years, the ...

LAST 30 PRESS RELEASES:

Science briefing: An update on GLP-1 drugs for obesity

Lower doses of immunotherapy for skin cancer give better results

Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

A sound defense: Noisy pupae puff away potential predators

Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

New findings support a chemo-free approach for treating Ph+ ALL

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

[Press-News.org] Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility
Standard road crossing intervals are often too short for older adults with limited mobility, research reveals